Marinus and Ceribell, Inc. agree to place handheld Ceribell Rapid Response EEG systems in hospitals in connection with its Phase 3 RSE clinical trial Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the enrollment of the first patient in a Phase 3 clinical trial of IV ganaxolone (RAISE trial) for the treatment of refractory status epilepticus (RSE), a life-threatening occurrence of continued or intermittent seizures lasting more than five minutes in duration without recovery of consciousness. RSE is considered a medical emergency that can cause permanent brain damage or death if not quickly controlled. The RAISE trial is a randomized, double-blind, placebo-controlled trial that will evaluate the efficacy and safety of IV ganaxolone in RSE patients who have failed benzodiazepines and two or more second line intravenous antiepileptic drugs (AEDs). The study will
Read the full article at: ir.marinuspharma.com
Latest posts by BioBuzz Media (see all)
- Penn cell therapy pioneer Dr. Carl June wins $1M prize - April 15, 2021
- Rockville’s MacroGenics Enters Research Collaboration with Sweden’s Alligator Bioscience to Develop a Novel Immunotherapy - April 15, 2021
- LGBT+ investment firm Gaingels joins American Gene Technologies’ mission to cure HIV, and other serious human diseases - April 15, 2021
- TEDCO’s Dr. Arti Santhanam: Bringing New Innovations to Market - April 13, 2021
- Arcellx Closes $115 Million Series C Financing to Advance its Pipeline of Adaptive and Controllable Cell Therapies - April 13, 2021
